Journal of Pharmaceutics & Drug Delivery ResearchISSN: 2325-9604

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

KRAS mutation in advanced lung cancer: Response

Yang Yuan,Ma Qianli

Kunming Medical University, China

Yunnan Cancer Hospital, China

: J Pharm Drug Deliv Res


Lung cancer is a malignant respiratory tumor with rapid development and poor prognosis. VATS(video-assisted thoracic surgery) is the main treatment for early lung cancer, but the majority of patients are diagnosed at stage IIIB or IV. Platinum-based chemotherapy regimen is currently considered key components of first-line chemotherapy for advanced lung cancer; however, there are no standard treatment plans for lung cancer with KRAS mutation. Apatinib has been successfully applied as third-line treatment for advanced gastric cancer and has shown high efficacy in the treatment of various cancer. Herein we report a case of advanced lung cancer harboring KRAS mutation in which apatinib was administered and a partial response was achieved after four months of treatment. To date, a 10 months of progression-free survival have been achieved. Adverse reactions can be controlled and the patient's quality of life has improved. Apatinib provides a new option for clinicians to treat patients with advanced KRASmutation lung cancer.


Yang Yuan has completed his master at the age of 27 years from Kunming Medical University. He is currently engaged in basic and clinical research of lung cancer.He has published more than 10 papers in journals around the world and has been serving as an oncology member of CSCO.


Track Your Manuscript

Awards Nomination

Recommended Conferences